At its core, tirzepatide is a dual GIP/GLP1 receptor agonist that was developed to reduce appetite, slow gastric emptying, and improve metabolic control
Consequently, a second method, Bayesian Latent Class Analysis-based Taxonomic Classification (BLCA
[DOI] [PubMed] [Google Scholar] 71.Vignane T., Filipovic M.R
(Patil and Mitra 2026) What is Laugier-Hunziker Syndrome
Several studies (Table 3) have shown that LA significantly reduces body fat mass, hepatic clearance of TG-rich lipoproteins, and lipid droplets through upregulating the expression levels of hepatic lipolytic enzymes (ATGL, acyl-CoA thioesterase [Acot1], Acot2, Acsf2, and Crat) and downregulating the expression levels of liver lipogenic enzymes (patatin-like phospholipase domain protein [Pnpla3], Pnpla5, Elovl6, Acly, sn-glycerol-3-phosphate acyltransferase 1 [Gpat], Aacs, FASN, ACC, and SCD-1)
#philippinedermatologicalsociety #dermatologist #dermauthority #ivdrip #Glutathione #skinlightening #edutok #skintok #fyp #foryoupage #fypviral | Philippine Dermatological Society
